Hologic Completes $22.8B Take-Private Deal with Blackstone and TPG
Medical technology company Hologic (NASDAQ: HOLX) completed its previously announced acquisition by private equity firms Blackstone and TPG on April 7, 2026, taking the diagnostics and women's health leader private at $76.00 per share in cash.
The Deal
The transaction values Hologic at approximately $22.8 billion based on the cash consideration alone. Shareholders receive $76.00 per share plus one contingent value right (CVR) that could provide up to an additional $3.00 per share based on future revenue milestones, potentially bringing the total value to $79.00 per share.
The deal structure reflects a collaborative approach between two major private equity players. Blackstone and TPG formed a joint venture vehicle, Hopper Parent Inc., to complete the acquisition, with Hologic continuing as a wholly-owned subsidiary of the new parent company.
As part of the closing, Hologic refinanced its existing debt obligations. The company repaid all outstanding amounts under its credit facility and initiated redemption of $400 million in 4.625% Senior Notes due 2028 and $950 million in 3.250% Senior Notes due 2029. Parent funded the acquisition through a combination of equity commitments from the private equity sponsors and new debt financing.
Strategic Rationale
The take-private transaction comes as Hologic has established itself as a leader in women's health diagnostics and medical technology. The company's portfolio includes breast health screening systems, molecular diagnostics, and surgical products focused on women's health conditions.
For Blackstone and TPG, the joint acquisition represents a significant bet on the healthcare technology sector. Private equity ownership typically allows companies to make longer-term strategic investments without the quarterly earnings pressure of public markets. This could enable Hologic to accelerate R&D initiatives, pursue strategic acquisitions, or restructure operations without public market scrutiny.
The inclusion of contingent value rights tied to revenue milestones suggests the buyers see significant growth potential in Hologic's business. The CVR structure aligns shareholder interests with the company's future performance under private ownership, providing additional upside if revenue targets are achieved.
What to Watch
The contingent value rights represent an interesting component for former shareholders to monitor. With up to $3.00 per share in additional payments possible based on revenue milestones, the ultimate deal value could reach $79.00 per share if targets are met. The specific revenue thresholds and timeline for these milestones will be detailed in the CVR Agreement filed with the SEC.
For employees holding equity awards, the treatment varies based on grant timing. Awards granted before October 21, 2025, converted to cash at closing, while more recent grants convert to cash awards that maintain their original vesting schedules. This approach helps retain key talent through the ownership transition.
The delisting from NASDAQ marks the end of Hologic's run as a public company. Following the Form 25 filing to delist from the exchange, the company will file Form 15 to terminate its SEC reporting obligations, significantly reducing disclosure requirements going forward.
From an industry perspective, the transaction continues the trend of take-private deals in the medical technology sector as private equity firms seek stable, cash-generative healthcare assets. The joint structure between Blackstone and TPG may become a template for other large healthcare deals where spreading risk and combining expertise benefits both sponsors.
The successful closing at the originally announced price of $76 per share, first revealed in October 2025, demonstrates deal certainty in an environment where regulatory scrutiny of private equity healthcare acquisitions has intensified. The six-month timeline from announcement to closing suggests a relatively smooth regulatory review process.
For the broader medical device and diagnostics sector, Hologic's take-private transaction at a substantial valuation may support multiples for comparable public companies, particularly those with strong positions in specialized healthcare markets.